Celldex Therapeutics, Inc. — Director's Dealing 2008

Sep 29, 2008

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-09-25

Reporting Person: LIPTON KAREN SHOOS (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2008-09-25	Non-Qualified Stock Option (right to buy)	$11.65	A	12000	Acquired	2018-09-25	Common Stock (12000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2: Such option vests in four equal quarterly installments beginning 12/25/2008.